CDC: Expanding EMS Naloxone Use Will Save Lives

Share this content:
CDC: Expanding EMS Naloxone Use Will Save Lives
CDC: Expanding EMS Naloxone Use Will Save Lives

(HealthDay News) -- Allowing more emergency medical service (EMS) workers to administer the prescription drug naloxone could reduce the number of overdose deaths caused by opioids, according to research published online April 23 in the American Journal of Public Health.

U.S. Centers for Disease Control and Prevention researchers reviewed nationwide data from 2012 and found that advanced EMS staffers were more likely than basic EMS staffers to administer naloxone. One of the big reasons: as of 2014, only 12 states allowed basic EMS staffers to administer naloxone for a suspected opioid overdose, but all 50 states allowed advanced EMS staffers to do so, the CDC researchers noted. They recommend expanding training on the administration of naloxone to all emergency service staffers, and helping basic EMS personnel meet the advanced certification requirements.

The researchers found that naloxone was most likely to be given to women, patients ages 20 to 29, and suburban residents. In general, the opioid overdose death rate was 45 percent higher in rural areas than in urban areas, but the use of naloxone by rural EMS staffers was only 22.5 percent higher than among urban EMS staffers.

"Opioid overdose deaths are devastating families and communities, especially in rural areas," CDC Director Tom Frieden, M.D., M.P.H., said in a CDC news release. "Many of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses. Having trained EMS staff to administer naloxone in rural areas will save lives."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »